Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Robert M. Jotte, Federico Cappuzzo et al.|The Lancet Respiratory Medicine|2019Cited by 937
Pivotal results of the Medtronic Vascular Talent Thoracic Stent Graft System: The VALOR TrialRonald M. Fairman, J. Michael Tuchek, Frank J. Criado et al.|Journal of Vascular Surgery|2008Cited by 299